Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.02, indicating a +2.24% shift from the previous trading day.
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Should You Invest in Humacyte, Inc. (HUMA) Based on Bullish Wall Street Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript
Humacyte, Inc. ( HUMA ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Laura Niklason - Founder, President, CEO & Director Dale Sander - CFO, Chief Corporate Development Officer & Treasurer Conference Call Participants Thomas Johnson - Lifesci Advisors, LLC Sneha Muthe - Barclays Bank PLC, Research Division Iseult McMahon - BTIG, LLC, Research Division Joshua Jennings - TD Cowen, Research Division Jason Kolbert - D. Boral Capital LLC, Research Division Bruce Jackson - The Benchmark Company, LLC, Research Division Swayampakula Ramakanth - H.C.
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.33 per share a year ago.
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.31, representing a -10% change from its previous close.
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.62, indicating a -4.14% shift from the previous trading day.
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
Humacyte, Inc. (HUMA) closed at $1.72 in the latest trading session, marking a +1.18% move from the prior day.
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.79, representing a +1.7% change from its previous close.
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.
